Pulmonary Carcinoid Surface Receptor Modulation Using Histone Deacetylase Inhibitors

Area of Science:

• Oncology
• Molecular Medicine
• Medical Imaging

Background:

• Pulmonary carcinoids are neuroendocrine tumors (NETs) representing 1-2% of lung cancers.
• Current [18F]-FDG PET/CT imaging is suboptimal due to low tumor metabolic activity.
• Somatostatin receptor subtype 2 (SSTR2)-targeted PET/CT is limited in patients with diminished SSTR2 expression.

Purpose of the Study:

• To investigate the potential of histone deacetylase (HDAC) inhibitors to upregulate SSTR2 expression in pulmonary carcinoids.
• To evaluate the efficacy of HDAC inhibitors in enhancing SSTR2 expression for improved imaging and treatment.

Main Methods:

• Administered non-cytotoxic doses of HDAC inhibitors (TDP-A, romidepsin, SAHA, AB3, VPA) to pulmonary carcinoid cell lines and xenografts.
• Confirmed SSTR2 upregulation in vitro and in vivo.
• Utilized PET/CT imaging with radiolabeled somatostatin analogs.

Main Results:

• HDAC inhibitors successfully upregulated SSTR2 expression in pulmonary carcinoid cell lines and xenografts.
• Confirmed SSTR2 induction in vitro and in vivo.
• Demonstrated potential for enhanced imaging and targeted therapy.

Conclusions:

• HDAC inhibitors can effectively increase SSTR2 expression in pulmonary carcinoids.
• This strategy offers a promising approach for improving diagnostic imaging and developing targeted therapies for patients with limited SSTR2 expression.
• Enhances eligibility for SSTR2-specific treatments and imaging modalities.